Tryp Therapeutics Performance
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Tryp Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Tryp Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Tryp Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 3.7 M |
Tryp |
Tryp Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in Tryp Therapeutics on December 21, 2024 and sell it today you would earn a total of 100.00 from holding Tryp Therapeutics or generate -100.0% return on investment over 90 days. Tryp Therapeutics is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded otc stocks are less volatile than Tryp, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Tryp Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tryp Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Tryp Therapeutics, and traders can use it to determine the average amount a Tryp Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| TRYPF |
Based on monthly moving average Tryp Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tryp Therapeutics by adding Tryp Therapeutics to a well-diversified portfolio.
Tryp Therapeutics Fundamentals Growth
Tryp OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Tryp Therapeutics, and Tryp Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tryp OTC Stock performance.
| Return On Equity | -9.22 | |||
| Return On Asset | -2.05 | |||
| Current Valuation | 4.17 M | |||
| Shares Outstanding | 96.42 M | |||
| Price To Book | 2.50 X | |||
| EBITDA | (7.36 M) | |||
| Cash And Equivalents | 2.85 M | |||
| Cash Per Share | 0.03 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (5.81 M) | |||
| Earnings Per Share | (0.13) X | |||
| Total Asset | 2.34 M | |||
Things to note about Tryp Therapeutics performance evaluation
Checking the ongoing alerts about Tryp Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Tryp Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tryp Therapeutics is not yet fully synchronised with the market data | |
| Tryp Therapeutics has some characteristics of a very speculative penny stock | |
| Tryp Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.49 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tryp Therapeutics has accumulated about 2.85 M in cash with (5.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03. | |
| Roughly 47.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Tryp Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tryp Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Tryp Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tryp Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tryp Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Tryp Therapeutics' otc stock. These opinions can provide insight into Tryp Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Tryp OTC Stock
If you are still planning to invest in Tryp Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tryp Therapeutics' history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |